A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-smallcell lung cancer

Concurrent chemoradiotherapy (CCRT) is the standard treatment option for unresectable locally advanced nonsmall- cell lung cancer (LA-NSCLC) (1). Radiotherapy with a dose of 60–66 Gy and platinum-based doublet chemotherapy are commonly used in CCRT. However, outcomes with the standard treatment are not satisfying with a median survival of approximately 20 months. Both locoregional tumor recurrence and distant metastasis are potential obstacles in the treatment of LA-NSCLC.